1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc.

MDGL
Madrigal Pharmaceuticals, Inc.US flagNASDAQ Global Select
488.15
USD
+35.29
- -
11.25BMarket Cap

Total Valuation

Madrigal Pharmaceuticals, Inc. carries a market capitalization of 11.25B, placing it among publicly traded companies globally. Its enterprise value stands at 12.17B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap11.25B
Enterprise Value12.17B

Share Statistics

Madrigal Pharmaceuticals, Inc. currently has 23.04M shares outstanding.

Shares Outstanding23.04M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 11.16, and the price-to-book ratio stands at -5.78.

PE RatioN/A
PS Ratio11.16
PB Ratio-5.78
P/TBV Ratio23.57
P/FCF Ratio-48.45
P/OCF Ratio-47.13

Enterprise Valuation

EV / Sales10.75
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

Madrigal Pharmaceuticals, Inc. maintains a current ratio of 3.50, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 63.91, indicating elevated leverage, while an interest coverage ratio of -11.63 demonstrates limited ability to service its debt obligations.

Current Ratio3.50
Quick Ratio2.96
Debt / Equity63.91
Debt / EBITDA-1.11
Interest Coverage-11.63

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-27.83
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover0.94

Stock Price Statistics

Madrigal Pharmaceuticals, Inc.'s stock has gained approximately 71.63602% over the past 52 weeks. The 50-day moving average sits at 514.00, while the 200-day moving average is 488.80.

Beta (5Y)N/A
52-Week Price Change71.63602%
50-Day Moving Average514.00
200-Day Moving Average488.80
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Madrigal Pharmaceuticals, Inc. generated 1.13B in revenue and converted that into -309.44M in net income, yielding earnings per share of -12.82. EBITDA reached -312.00M, while operating income came in at -313.51M.

Revenue1.13B
Gross Profit1.05B
Operating Income-313.51M
Pretax Income-309.44M
Net Income-309.44M
EBITDA-312.00M
EBIT-313.51M
Earnings Per Share (EPS)-12.82

Balance Sheet

Madrigal Pharmaceuticals, Inc. holds 812.77M in cash and equivalents against 347.31M in total debt, resulting in a net debt position of 113.30M. Total book value stands at -2.18B, with working capital of 844.05M providing operational flexibility.

Cash & Cash Equivalents812.77M
Total Debt347.31M
Net Debt113.30M
Equity (Book Value)-2.18B
Book Value Per Share-90.52
Working Capital844.05M

Cash Flow

Madrigal Pharmaceuticals, Inc. produced -268.10M in operating cash flow over the past twelve months. After subtracting -7.32M in capital expenditures, free cash flow totaled -275.41M - equivalent to -11.41 per share.

Operating Cash Flow-268.10M
Capital Expenditures-7.32M
Free Cash Flow-275.41M
FCF Per Share-11.41

Margins

Madrigal Pharmaceuticals, Inc. operates with a gross margin of 93.07, reflecting its pricing power and cost economics. The operating margin of -27.68 and net profit margin of -27.32 provide insight into operational efficiency.

Gross Margin93.07
Operating Margin-27.68
Pretax Margin-27.32
Profit Margin-27.32
EBITDA Margin-27.55

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-1.98
FCF Yield-2.06

Stock Splits

Madrigal Pharmaceuticals, Inc.'s most recent stock split took place on July 25, 2016 with a 35:1 split ratio.

Last Split Date7/25/2016
Split Ratio35:1

Scores

Madrigal Pharmaceuticals, Inc. posts an Altman Z-Score of 9.49, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score9.49